UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 30, 2006
SAFETEK INTERNATIONAL, INC.
(Exact name of Registrant as specified in its charter)
Delaware 33-22175 75-2226896
-------- -------- ----------
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
23 Aminadav St.
Tel Aviv, Israel, 67898
(Address of principal executive offices)
+972-3-561-3468
(Registrant's Telephone Number, Including Area Code)
--------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
1
SECTION 1 - REGISTRANT'S BUSINESS AND OPERATIONS
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
As previously disclosed, on January 4, 2006, Safetek International, Inc. (the
"Registrant") and Matrix Pharma, Inc., a Delaware corporation ("Matrix"), closed
on the transaction contemplated by the Exclusive Patent and Know How License
Option Agreement, dated December 28, 2005 (the "License Option Agreement").
Pursuant to the License Option Agreement, the Registrant acquired from Matrix an
option to purchase an exclusive, world-wide license in all of Matrix's
intellectual property rights in its Thrombin inhibition compounds. Such
transaction is more fully discussed in the Registrant's Form 8-K, dated January
4, 2006 and filed with the Securities and Exchange Commission on January 5,
2006.
Pursuant to the License Option Agreement, the Registrant may have exercised such
option at any time until March 31, 2006. On March 30, 2006, the Registrant and
Matrix signed an amendment extending the exercise date of the option to May 15,
2006. In consideration for Matrix's agreement to extend the exercise date to May
15, 2006, the Registrant agreed that, within five business days after the
Registrant files a registration statement, the Registrant will pay Matrix
$15,000. Such amount will be deducted from the amount that the Registrant is
required to pay to Matrix upon exercise of the option.
For all the terms of the amendment to the License Option Agreement, reference is
hereby made to such amendment annexed hereto as Exhibit 10.5. All statements
made herein concerning such amendment are qualified by references to said
exhibit.
SECTION 9-FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(a) Financial Statements of business acquired. Not Applicable
(b) Pro forma financial information. Not Applicable
(c) Exhibits
Exhibit 10.5 Amendment, dated March 31, 2006, between the Registrant and Matrix
Pharma, Inc.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SAFETEK INTERNATIONAL, INC.
(Registrant)
By: /s/ Amnon Presler
-----------------------
Name: Amnon Presler
Title: Chief Executive Officer
Date: March 31, 2006
3